No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Does Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Deserve A Spot On Your Watchlist?
The price of natural bezoar has risen under pressure, and Zhangzhou Pientzehuang Pharmaceutical's profit growth rate has returned to that of ten years ago.
The "Medicine Mace" Zhangzhou Pientzehuang Pharmaceutical (600436.SH) is entering a "slowdown" period. On January 24th, Zhangzhou Pientzehuang Pharmaceutical released the 2024 performance brief...
The rise in raw material costs has led to a slowdown in the net profit growth of Zhangzhou Pientzehuang Pharmaceutical in 2024.
Encountering a Waterloo.
Announcement of Zhangzhou Pianziying Pharmaceutical Co., Ltd. on the 2024 Annual Results Report
Express News | Zhangzhou Pientzehuang Pharmaceutical Prelim 2024 Net Profit up 6.3% Y/Y
102884128 : getting disappointed with this counter. every day drop.